AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24650818 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous sexual victimization (PSV)
Number of subjects: 120
Study 22764609 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg)
Number of subjects: 18
Study 22764609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (5 mg)
Number of subjects: 18
Study 22764609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20923474 — intervention group
Group type: EXPERIMENTAL
Intervention: Local dry heat + Electrical Stimulation (ES)
Number of subjects: 20
Study 20923474 — intervention group
Group type: COMPARATOR
Intervention: Local dry heat only
Number of subjects: 20
Study 18703803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy (OAT) related ICH
Number of subjects: 303
Study 18703803 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ICH (SICH)
Number of subjects: 303
Study 15741530 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate (5 mg) and mecobalamin (1500 microg)
Number of subjects: 628
Study 15741530 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 628
Study 15741530 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate and mecobalamin
Number of subjects: 628
Study 12675867 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-bonded cellulose membrane dialyzer (EE)
Number of subjects: 34
Study 12675867 — intervention group
Group type: COMPARATOR
Intervention: Cellulose membrane (SU)
Number of subjects: 34
Study 10819408 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral administration of beta-blocker
Number of subjects: 44
Study 10819408 — intervention group
Group type: COMPARATOR
Intervention: Baseline recordings using FFT spectral method
Number of subjects: 44
Study 10819408 — intervention group
Group type: COMPARATOR
Intervention: Both spectral methods
Number of subjects: 44
Study 10819408 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency component of heart rate variability
Number of subjects: 44
Study 8670033 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser conditioning
Number of subjects: 0
Study 8670033 — intervention group
Group type: COMPARATOR
Intervention: Acid etching
Number of subjects: 0
Study 1353506 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.20 mg/kg)
Number of subjects: 17
Study 1353506 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (0.25 mg/kg)
Number of subjects: 17
Study 1353506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (0.04 mg/kg)
Number of subjects: 17
Study 1353506 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 17
Study 6329254 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral evening primrose oil
Number of subjects: 41
Study 6329254 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 41
Study 31122997 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, individualised information via the Internet
Number of subjects: 0
Study 31122997 — intervention group
Group type: EXPERIMENTAL
Intervention: Untailored information
Number of subjects: 0
Study 31122997 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 29932807 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 246
Study 29932807 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 246
Study 29932807 — intervention group
Group type: COMPARATOR
Intervention: Control (no practice)
Number of subjects: 246
Study 26986848 — intervention group
Group type: EXPERIMENTAL
Intervention: Free screening offer
Number of subjects: 3124
Study 26986848 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation with a fee of 100 SEK (≈11 €)
Number of subjects: 3124
Study 24486563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (16 IU)
Number of subjects: 50
Study 24486563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22340552 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer navigation‐assisted total knee replacement
Number of subjects: 82
Study 19590506 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40-80 mg per day) plus Hydrochlorothiazide (12.5 mg per day)
Number of subjects: 75
Study 19590506 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5-7.5 mg per day)
Number of subjects: 75
Study 17368522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy with cisplatin
Number of subjects: 0
Study 17368522 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) chemotherapy
Number of subjects: 0
Study 15777483 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplementation provided by the World Food Programme
Number of subjects: 360
Study 15777483 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional oil provided to some families
Number of subjects: 360
Study 11973194 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.08 microg x kg(‐1) x min(‐1))
Number of subjects: 20
Study 11973194 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study 9838801 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced sodium intake
Number of subjects: 0
Study 9838801 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study 9838801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary interventions
Number of subjects: 0
Study 7657286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (NAD) plus isosorbide-5-mononitrate (I5M)
Number of subjects: 81
Study 7657286 — intervention group
Group type: COMPARATOR
Intervention: Nadolol (NAD) alone
Number of subjects: 81
Study 2558700 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.4 nmol kg‐1 min‐1)
Number of subjects: 0
Study 2558700 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study 2558700 — intervention group
Group type: COMPARATOR
Intervention: CWT (mental stress)
Number of subjects: 0
Study 1104668 — intervention group
Group type: EXPERIMENTAL
Intervention: Halcinonide cream applied three times daily for two to three weeks
Number of subjects: 392
Study 1104668 — intervention group
Group type: COMPARATOR
Intervention: Fluocinonide cream applied three times daily for two to three weeks
Number of subjects: 392
Study 1104668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both creams
Number of subjects: 392
Study 30985671 — intervention group
Group type: EXPERIMENTAL
Intervention: Real laser acupuncture treatment (LAT)
Number of subjects: 32
Study 30985671 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture treatment
Number of subjects: 32
Study 28622950 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300U/mL (Gla-300)
Number of subjects: 878
Study 28622950 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100U/mL (Gla-100)
Number of subjects: 878
Study 25760346 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided antibiotic treatment for either 3 or 10 days
Number of subjects: 184
Study 25760346 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic treatment for 10 days
Number of subjects: 184
Study 23247001 — intervention group
Group type: EXPERIMENTAL
Intervention: Original PQAS
Number of subjects: 41
Study 23247001 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised PQAS
Number of subjects: 41
Study 21595618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure tone masking‐tinnitus retraining therapy (TRT)
Number of subjects: 91
Study 21595618 — intervention group
Group type: COMPARATOR
Intervention: Betahistine dihydrochloride
Number of subjects: 91
Study 21595618 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 91
Study 18534547 — intervention group
Group type: EXPERIMENTAL
Intervention: Retransfusion drains removed at 6 hours postoperatively
Number of subjects: 80
Study 18534547 — intervention group
Group type: COMPARATOR
Intervention: Retransfusion drains removed at 24 hours postoperatively
Number of subjects: 80
Study 15707477 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 2383
Study 15707477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2383
Study 12622930 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine 100 mg daily (n = 322)
Number of subjects: 429
Study 12622930 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 107)
Number of subjects: 429
Study 10604415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 34
Study 10604415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 7486295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.08 mg.kg-1)
Number of subjects: 152
Study 7486295 — intervention group
Group type: COMPARATOR
Intervention: No Vecuronium (Vecu0 group)
Number of subjects: 152
Study 1936510 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ketorolac tromethamine given orally four times daily for 3 days
Number of subjects: 100
Study 1936510 — intervention group
Group type: COMPARATOR
Intervention: 500 mg diflunisal given orally twice daily plus placebo twice daily for 3 days
Number of subjects: 100
Study 1936510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 100
Study 1936510 — intervention group
Group type: COMPARATOR
Intervention: Diflunisal
Number of subjects: 100
Study 7117684 — intervention group
Group type: EXPERIMENTAL
Intervention: 330 mg ultramicrosize griseofulvin tablet
Number of subjects: 16
Study 7117684 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 165 mg ultramicrosize griseofulvin tablets
Number of subjects: 16
Study 7117684 — intervention group
Group type: COMPARATOR
Intervention: 500 mg microsize griseofulvin formulation
Number of subjects: 16
Study 30690902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT‐AFL)
Number of subjects: 115
Study 30690902 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 115
Study 28559749 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy program plus SNAG (3 times per week for 1 month)
Number of subjects: 42
Study 28559749 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy program without SNAG (3 times per week for 1 month)
Number of subjects: 42
Study 26270684 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for asymptomatic bacteriuria (AB) in group B
Number of subjects: 550
Study 26270684 — intervention group
Group type: COMPARATOR
Intervention: No treatment for asymptomatic bacteriuria in group A
Number of subjects: 550
Study 25022130 — intervention group
Group type: EXPERIMENTAL
Intervention: Navel-warming therapy combined with western medication
Number of subjects: 120
Study 25022130 — intervention group
Group type: COMPARATOR
Intervention: Western medication alone
Number of subjects: 120
Study 22526517 — intervention group
Group type: EXPERIMENTAL
Intervention: FLU 1200 mg/day + 5-FC 100 mg/kg/day for 14 days + AmB 1 mg/kg/day for 7 days
Number of subjects: 40
Study 22526517 — intervention group
Group type: COMPARATOR
Intervention: FLU 1200 mg/day + AmB 1 mg/kg/day for 7 days
Number of subjects: 40
Study 22526517 — intervention group
Group type: COMPARATOR
Intervention: FLU 1200 mg/day + 5-FC 100 mg/kg/day for 14 days
Number of subjects: 40
Study 22526517 — intervention group
Group type: COMPARATOR
Intervention: FLU alone
Number of subjects: 40
Study 22526517 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of 5-FC
Number of subjects: 40
Study 22526517 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of AmB
Number of subjects: 40
Study 19943469 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 126
Study 19943469 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 126
Study 19943469 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 126
Study 19943469 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 126
Study 17329297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispronicline 50 mg
Number of subjects: 76
Study 17329297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispronicline 100 mg
Number of subjects: 76
Study 17329297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispronicline 150 mg
Number of subjects: 76
Study 17329297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 15385365 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 21
Study 15385365 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly extracted auditory evoked potentials index (AAI)
Number of subjects: 21
Study 15385365 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BIS and AAI
Number of subjects: 21
Study 11435270 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antipsychotic treatment
Number of subjects: 59
Study 11435270 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (specifically olanzapine)
Number of subjects: 59
Study 10235018 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) for symptomatic plaques
Number of subjects: 57
Study 10235018 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) for asymptomatic plaques
Number of subjects: 57
Study 10235018 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic contralateral carotid artery disease followed with CEA
Number of subjects: 57
Study 7543344 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled acetaldehyde
Number of subjects: 9
Study 7543344 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled histamine
Number of subjects: 9
Study 2712260 — intervention group
Group type: EXPERIMENTAL
Intervention: Nellcor N-200
Number of subjects: 46
Study 2712260 — intervention group
Group type: COMPARATOR
Intervention: Nellcor N-100
Number of subjects: 46
Study 2712260 — intervention group
Group type: EXPERIMENTAL
Intervention: Various fractions of oxygen
Number of subjects: 46
Study 2712260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 46
Study 2712260 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 46
Study 238792 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg. monohydrochloride salt of flurazepam
Number of subjects: 40
Study 238792 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg. dihydrochloride salt of flurazepam
Number of subjects: 40
Study 238792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31237451 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-hour fast
Number of subjects: 0
Study 31237451 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine-conjugated deoxycholic acid (gDCA) supplementation
Number of subjects: 0
Study 31237451 — intervention group
Group type: COMPARATOR
Intervention: Overnight fast
Number of subjects: 0
Study 31237451 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour mixed meal test with gDCA
Number of subjects: 0
Study 31237451 — intervention group
Group type: COMPARATOR
Intervention: 4-hour mixed meal test without gDCA
Number of subjects: 0
Study 28379964 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000mg ω-3 supplements
Number of subjects: 64
Study 28379964 — intervention group
Group type: COMPARATOR
Intervention: Control capsule
Number of subjects: 64
Study 25986476 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU care for 24 hours
Number of subjects: 104
Study 23899642 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg THC
Number of subjects: 30
Study 23899642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21737071 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed embryos
Number of subjects: 0
Study 21737071 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryos
Number of subjects: 0
Study 20178280 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory feedback
Number of subjects: 15
Study 20178280 — intervention group
Group type: COMPARATOR
Intervention: Visual feedback
Number of subjects: 15
Study 20178280 — intervention group
Group type: COMPARATOR
Intervention: Auditory + Visual feedback
Number of subjects: 15
Study 16420204 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight subjects
Number of subjects: 2684
Study 16420204 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I obesity (BMI 30.0-34.9 kg/m2)
Number of subjects: 2684
Study 16420204 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II obesity (BMI >35.0 kg/m2)
Number of subjects: 2684
Study 14738232 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance inspiratory muscle training (IMT) for one year
Number of subjects: 38
Study 14738232 — intervention group
Group type: COMPARATOR
Intervention: Very low load training (control group)
Number of subjects: 38
Study 11641004 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay (WTP) for mammography among different ethnic groups
Number of subjects: 1465
Study 11641004 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial link to breast cancer
Number of subjects: 1465
Study 9028539 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal history of hip fracture
Number of subjects: 12816
Study 9028539 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal history of hip fracture
Number of subjects: 12816
Study 9028539 — intervention group
Group type: COMPARATOR
Intervention: Control group (no maternal hip fracture)
Number of subjects: 12816
Study 8505112 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (70 mmol sodium intake per day)
Number of subjects: 210
Study 8505112 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride supplementation (1 mmol/kg potassium chloride per day)
Number of subjects: 210
Study 8505112 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal diet plus placebo capsule)
Number of subjects: 210
Study 3277760 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone‐iodine
Number of subjects: 271
Study 3277760 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated triple dye application
Number of subjects: 271
Study 3277760 — intervention group
Group type: COMPARATOR
Intervention: All methods
Number of subjects: 271
Study 31895461 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected nonclinical time (2 hours per week)
Number of subjects: 19
Study 31431445 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercises in combination with lumbar force accuracy training exercises
Number of subjects: 94
Study 31431445 — intervention group
Group type: COMPARATOR
Intervention: Strengthening exercises alone
Number of subjects: 94
Study 28316019 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg single oral dose)
Number of subjects: 26
Study 28316019 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MDR1 3435C>T and body mass index as covariates for ka 1
Number of subjects: 26
Study 28316019 — intervention group
Group type: EXPERIMENTAL
Intervention: Body surface area as a covariate
Number of subjects: 26
Study 25441178 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 45
Study 25441178 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic plus strength training with linear periodization (LP)
Number of subjects: 45
Study 25441178 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic plus strength training with daily undulating periodization (DUP)
Number of subjects: 45
Study 24043256 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 78
Study 24043256 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Rosiglitazone (ROSI)
Number of subjects: 78
Study 24043256 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Lovaza (LOV)
Number of subjects: 78
Study 21612912 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-oncological intervention in high-risk patients
Number of subjects: 131
Study 21612912 — intervention group
Group type: COMPARATOR
Intervention: Observation group (control)
Number of subjects: 131
Study 18712761 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term survivor model with bivariate random effects applied to leukemia patients
Number of subjects: 0
Study 18712761 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term survivor model with bivariate random effects applied to carcinoma patients
Number of subjects: 0
Study 21205873 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of Return (IOR) during visual search tasks
Number of subjects: 0
Study 21205873 — intervention group
Group type: COMPARATOR
Intervention: Control locations (not specified)
Number of subjects: 0
Study 16110714 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 300
Study 16110714 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 300
Study 11886009 — intervention group
Group type: EXPERIMENTAL
Intervention: EAP regimen (etoposide, adriamycin and cisplatin) followed by Machover schedule (fluorouracil and folinic acid)
Number of subjects: 274
Study 11886009 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned)
Number of subjects: 274
Study 9848504 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP Step I soy‐protein diet
Number of subjects: 26
Study 9848504 — intervention group
Group type: COMPARATOR
Intervention: NCEP Step I animal protein diet
Number of subjects: 26
Study 7496915 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified surface antigen vaccine (SAV)
Number of subjects: 38
Study 7496915 — intervention group
Group type: COMPARATOR
Intervention: Whole virus vaccine
Number of subjects: 38
Study 2573098 — intervention group
Group type: EXPERIMENTAL
Intervention: Perazine
Number of subjects: 0
Study 2573098 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 0
Study 2573098 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluoperazine
Number of subjects: 0
Study 2573098 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study 2573098 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 1251319 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis group (14 patients)
Number of subjects: 30
Study 1251319 — intervention group
Group type: COMPARATOR
Intervention: Sepsis group (16 patients)
Number of subjects: 30